FIELD: medicine; pharmaceuticals.
SUBSTANCE: pharmaceutical composition comprises one of the compounds of formula I, where A is CH3- or CH2=CH-, and B is -CH=CH-, [-CH2-]x or [CH2-]y, where x is an integer from 1 to 10, where y is an integer from 1 to 10, provided that: if A is CH3-, B is [-CH2-]x; if A is CH2=CH-, B is [-CH2-]y, in an effective amount and one or more pharmaceutically acceptable excipients.
(I).
EFFECT: invention relates to a pharmaceutical composition for the treatment of cancer.
11 cl, 9 dwg, 4 ex
Title | Year | Author | Number |
---|---|---|---|
INGENOL DERIVATIVES FOR REACTIVATION OF LATENT HIV VIRUS | 2013 |
|
RU2609512C2 |
INGENOL-3-ACYLATES I | 2011 |
|
RU2575349C2 |
3-ACYLINGENOLES II | 2011 |
|
RU2575350C2 |
INGENOL-3-ACYLATES III AND INGENOL-3-CARBAMATES | 2011 |
|
RU2572549C2 |
SOMATOSTATIN ANALOGUES | 2001 |
|
RU2287533C2 |
PHARMACEUTICAL COMPOSITION FOR CANCER AND VIRAL DISEASE TREATMENT, METHOD OF CANCER TREATMENT, METHOD OF VIRAL INFECTION TREATMENT BASED ON THEREOF | 1996 |
|
RU2177316C2 |
AMATOXIN-CONJUGATES WITH IMPROVED LINKERS | 2011 |
|
RU2601411C2 |
ALBUMIN-BINDING PRODRUGS BASED ON AURISTATIN E DERIVATIVES | 2018 |
|
RU2795101C2 |
DRUG DELIVERY SYSTEMS BASED ON MAYTANSINOID | 2018 |
|
RU2783076C2 |
CRYSTALLINE INGENOL MEBUTATE | 2011 |
|
RU2572618C2 |
Authors
Dates
2018-07-27—Published
2013-10-31—Filed